Concord Biotech gets USFDA approval for Mycophenolate Mofetil Oral Suspension

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹1180.00

prior close

₹1230.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.0%+1.3% vs market

Pharmaceuticals peers, median of 163sector-0.0%+1.4% vs sector

On the reaction day the stock moved 1.3 pts more than Nifty Smallcap 250 and 1.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.9

10m

-1.7

15m

-1.3

30m

+1.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4+0.0+1.3-0.0+1.4

Next day

+4.7+0.6+4.1+0.2+4.5

+3.8+0.6+3.1+0.5+3.3

+1.2-1.2+2.3-0.2+1.4

+8.5+0.2+8.3+0.7+7.8

+11.8-1.0+12.8+0.1+11.8

+15.0+0.8+14.2+0.8+14.2

15d

+9.2+4.9+4.3+4.4+4.8

+8.6+6.2+2.4+6.5+2.2

+19.5+7.2+12.3+6.3+13.2

+22.8+8.8+14.0+7.9+14.9

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Concord Biotech has received USFDA approval for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. The drug is an immunosuppressant used to prevent organ rejection in kidney, heart, or liver transplant patients aged 3 months and older. The US market for this drug is estimated at around US$30 million. The approval supports the company’s growth strategy and strengthens its position in the US and international markets.

Likely market impact

Positive; opens access to a US$30 million US market, supporting future revenue and long-term growth strategy.